| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 49 | 2026 | 125 | 17.660 |
Why?
|
| Eye Infections, Bacterial | 54 | 2025 | 129 | 15.740 |
Why?
|
| Bacillus cereus | 22 | 2025 | 59 | 8.140 |
Why?
|
| Staphylococcus aureus | 23 | 2026 | 125 | 5.470 |
Why?
|
| Gram-Positive Bacterial Infections | 15 | 2025 | 91 | 5.210 |
Why?
|
| Staphylococcal Infections | 18 | 2026 | 90 | 5.190 |
Why?
|
| Mice, Inbred C57BL | 34 | 2026 | 1684 | 3.850 |
Why?
|
| Disease Models, Animal | 32 | 2026 | 1524 | 3.290 |
Why?
|
| Bacillus thuringiensis | 6 | 2021 | 19 | 2.950 |
Why?
|
| Retina | 21 | 2025 | 446 | 2.300 |
Why?
|
| Mice | 37 | 2026 | 4867 | 2.260 |
Why?
|
| Bacterial Toxins | 8 | 2026 | 281 | 2.190 |
Why?
|
| Animals | 68 | 2026 | 10802 | 2.190 |
Why?
|
| Keratitis | 16 | 2025 | 31 | 2.170 |
Why?
|
| Anti-Bacterial Agents | 14 | 2025 | 540 | 2.150 |
Why?
|
| Toll-Like Receptor 4 | 7 | 2025 | 72 | 2.010 |
Why?
|
| Immunity, Innate | 5 | 2025 | 234 | 1.950 |
Why?
|
| Virulence | 21 | 2023 | 155 | 1.810 |
Why?
|
| Electroretinography | 16 | 2025 | 180 | 1.810 |
Why?
|
| Bacillus | 5 | 2022 | 25 | 1.770 |
Why?
|
| Cornea | 11 | 2025 | 72 | 1.650 |
Why?
|
| Blood-Retinal Barrier | 5 | 2016 | 27 | 1.580 |
Why?
|
| Inflammation | 8 | 2023 | 670 | 1.570 |
Why?
|
| Chemokine CCL2 | 2 | 2024 | 47 | 1.560 |
Why?
|
| Klebsiella Infections | 4 | 2014 | 12 | 1.410 |
Why?
|
| Bacterial Proteins | 11 | 2022 | 505 | 1.390 |
Why?
|
| Toll-Like Receptor 2 | 7 | 2025 | 34 | 1.370 |
Why?
|
| Klebsiella pneumoniae | 6 | 2016 | 29 | 1.250 |
Why?
|
| Rabbits | 27 | 2026 | 281 | 1.210 |
Why?
|
| Hemolysin Proteins | 3 | 2026 | 56 | 1.200 |
Why?
|
| Neutrophils | 11 | 2021 | 185 | 1.190 |
Why?
|
| Uveitis | 4 | 2022 | 23 | 1.150 |
Why?
|
| Membrane Glycoproteins | 2 | 2020 | 149 | 1.140 |
Why?
|
| Colony Count, Microbial | 19 | 2025 | 82 | 1.130 |
Why?
|
| Chemokine CCL3 | 2 | 2024 | 9 | 1.030 |
Why?
|
| Bacillaceae Infections | 5 | 2006 | 7 | 1.030 |
Why?
|
| Leukocidins | 1 | 2025 | 4 | 0.900 |
Why?
|
| Phosphatidylcholines | 2 | 2020 | 45 | 0.810 |
Why?
|
| Cytokines | 8 | 2020 | 457 | 0.730 |
Why?
|
| Chemokine CXCL2 | 1 | 2021 | 6 | 0.710 |
Why?
|
| Chemokine CXCL10 | 1 | 2021 | 22 | 0.700 |
Why?
|
| Metalloproteases | 1 | 2021 | 7 | 0.690 |
Why?
|
| Metalloendopeptidases | 1 | 2021 | 40 | 0.680 |
Why?
|
| Fluoroquinolones | 4 | 2013 | 15 | 0.660 |
Why?
|
| Vitreous Body | 7 | 2025 | 23 | 0.640 |
Why?
|
| Mice, Knockout | 6 | 2025 | 878 | 0.610 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2020 | 100 | 0.590 |
Why?
|
| Immunomodulation | 1 | 2019 | 20 | 0.590 |
Why?
|
| Aza Compounds | 3 | 2013 | 11 | 0.590 |
Why?
|
| Biomimetic Materials | 1 | 2019 | 20 | 0.580 |
Why?
|
| Quinolines | 3 | 2013 | 35 | 0.580 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2020 | 102 | 0.580 |
Why?
|
| Glucocorticoids | 4 | 2016 | 115 | 0.570 |
Why?
|
| Peroxidase | 6 | 2024 | 39 | 0.560 |
Why?
|
| Nanostructures | 1 | 2019 | 64 | 0.550 |
Why?
|
| Humans | 28 | 2023 | 29202 | 0.510 |
Why?
|
| Bacteria | 4 | 2013 | 286 | 0.510 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 112 | 0.500 |
Why?
|
| Ciprofloxacin | 9 | 2000 | 22 | 0.490 |
Why?
|
| Chemokine CXCL1 | 1 | 2016 | 7 | 0.490 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 15 | 0.490 |
Why?
|
| Chemokines | 4 | 2020 | 74 | 0.480 |
Why?
|
| Anti-Infective Agents | 4 | 2009 | 78 | 0.480 |
Why?
|
| Flagella | 2 | 2014 | 29 | 0.480 |
Why?
|
| Ophthalmic Solutions | 11 | 2009 | 27 | 0.470 |
Why?
|
| Retinal Vessels | 2 | 2016 | 75 | 0.470 |
Why?
|
| Vitrectomy | 2 | 2016 | 8 | 0.470 |
Why?
|
| Male | 13 | 2025 | 14120 | 0.470 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2015 | 31 | 0.450 |
Why?
|
| Interleukin-6 | 1 | 2016 | 198 | 0.430 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2014 | 5 | 0.430 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 210 | 0.420 |
Why?
|
| Female | 10 | 2026 | 15819 | 0.400 |
Why?
|
| Virulence Factors | 4 | 2022 | 45 | 0.380 |
Why?
|
| Capillary Permeability | 2 | 2012 | 56 | 0.370 |
Why?
|
| Chemokines, CXC | 2 | 2023 | 12 | 0.370 |
Why?
|
| Eye | 4 | 2021 | 36 | 0.370 |
Why?
|
| Exotoxins | 3 | 2025 | 7 | 0.360 |
Why?
|
| RNA, Bacterial | 1 | 2011 | 65 | 0.350 |
Why?
|
| Pseudomonas Infections | 8 | 2022 | 25 | 0.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 252 | 0.320 |
Why?
|
| Vancomycin | 5 | 2011 | 59 | 0.310 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 93 | 0.300 |
Why?
|
| Ependymoglial Cells | 2 | 2020 | 32 | 0.300 |
Why?
|
| Flow Cytometry | 4 | 2025 | 292 | 0.300 |
Why?
|
| Cells, Cultured | 4 | 2021 | 1024 | 0.300 |
Why?
|
| NF-kappa B | 2 | 2020 | 191 | 0.290 |
Why?
|
| Bacterial Adhesion | 3 | 2020 | 29 | 0.270 |
Why?
|
| Mutation | 3 | 2011 | 875 | 0.270 |
Why?
|
| Polymerase Chain Reaction | 4 | 2018 | 270 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 336 | 0.260 |
Why?
|
| Genotype | 3 | 2023 | 462 | 0.250 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2007 | 24 | 0.250 |
Why?
|
| Trans-Activators | 3 | 2003 | 118 | 0.250 |
Why?
|
| Dexamethasone | 3 | 2008 | 63 | 0.240 |
Why?
|
| Tobramycin | 4 | 1995 | 13 | 0.240 |
Why?
|
| Pseudomonas aeruginosa | 5 | 2022 | 72 | 0.240 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 169 | 0.240 |
Why?
|
| Retinal Diseases | 1 | 2006 | 47 | 0.240 |
Why?
|
| Gene Expression Regulation, Bacterial | 4 | 2022 | 158 | 0.230 |
Why?
|
| Aqueous Humor | 4 | 2017 | 24 | 0.230 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2008 | 151 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 128 | 0.200 |
Why?
|
| Treatment Outcome | 2 | 2025 | 2442 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 466 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2019 | 133 | 0.170 |
Why?
|
| Ofloxacin | 2 | 2000 | 4 | 0.170 |
Why?
|
| Preservation, Biological | 1 | 2021 | 11 | 0.170 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 34 | 0.170 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2020 | 7 | 0.160 |
Why?
|
| Th17 Cells | 1 | 2020 | 33 | 0.160 |
Why?
|
| Uvea | 1 | 2020 | 2 | 0.160 |
Why?
|
| HL-60 Cells | 1 | 2020 | 22 | 0.160 |
Why?
|
| Serpins | 1 | 2020 | 31 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 98 | 0.150 |
Why?
|
| Spleen | 1 | 2020 | 114 | 0.150 |
Why?
|
| Dacryocystitis | 1 | 2019 | 5 | 0.150 |
Why?
|
| Disease Resistance | 1 | 2019 | 16 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2020 | 81 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 82 | 0.150 |
Why?
|
| Gram-Positive Bacteria | 1 | 1999 | 33 | 0.150 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2020 | 67 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 215 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 74 | 0.150 |
Why?
|
| Models, Animal | 1 | 2019 | 130 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 257 | 0.140 |
Why?
|
| Corneal Ulcer | 3 | 1993 | 12 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 37 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2020 | 158 | 0.140 |
Why?
|
| Nanotechnology | 1 | 2019 | 68 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2019 | 90 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 285 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 171 | 0.140 |
Why?
|
| Tight Junctions | 2 | 2009 | 29 | 0.140 |
Why?
|
| Polymers | 1 | 2019 | 118 | 0.140 |
Why?
|
| Microarray Analysis | 1 | 2018 | 65 | 0.140 |
Why?
|
| Analysis of Variance | 1 | 2018 | 393 | 0.130 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 58 | 0.130 |
Why?
|
| Collagen | 2 | 1994 | 157 | 0.120 |
Why?
|
| Bacterial Load | 1 | 2016 | 6 | 0.120 |
Why?
|
| Evans Blue | 1 | 2016 | 7 | 0.120 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 17 | 0.120 |
Why?
|
| Iodates | 1 | 2016 | 11 | 0.120 |
Why?
|
| Dextrans | 1 | 2016 | 23 | 0.120 |
Why?
|
| Methicillin Resistance | 2 | 1994 | 7 | 0.120 |
Why?
|
| Angiography | 1 | 2016 | 35 | 0.120 |
Why?
|
| Coloring Agents | 1 | 2016 | 37 | 0.120 |
Why?
|
| Cefazolin | 2 | 1992 | 6 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 478 | 0.120 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 12 | 0.110 |
Why?
|
| DNA, Bacterial | 4 | 2006 | 314 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 242 | 0.110 |
Why?
|
| Chemotactic Factors | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cell Survival | 1 | 2016 | 422 | 0.110 |
Why?
|
| Flagellin | 1 | 2014 | 9 | 0.110 |
Why?
|
| Staphylococcal Protein A | 1 | 1994 | 3 | 0.110 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 19 | 0.110 |
Why?
|
| Blotting, Western | 3 | 2014 | 515 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2014 | 43 | 0.100 |
Why?
|
| Phenotype | 2 | 2006 | 689 | 0.100 |
Why?
|
| Streptococcus pneumoniae | 2 | 2009 | 29 | 0.100 |
Why?
|
| RNA | 1 | 2014 | 111 | 0.100 |
Why?
|
| Eye Infections, Viral | 1 | 1993 | 5 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2011 | 25 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 329 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 1994 | 236 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 1993 | 114 | 0.090 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2011 | 13 | 0.090 |
Why?
|
| Posterior Eye Segment | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 646 | 0.080 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2009 | 4 | 0.080 |
Why?
|
| Benzalkonium Compounds | 2 | 2009 | 9 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 303 | 0.080 |
Why?
|
| Chemokine CCL20 | 1 | 2010 | 7 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 1033 | 0.080 |
Why?
|
| Biological Availability | 2 | 2008 | 44 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 1 | 2009 | 7 | 0.070 |
Why?
|
| Occludin | 1 | 2009 | 12 | 0.070 |
Why?
|
| Fibrin | 1 | 2009 | 17 | 0.070 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2009 | 17 | 0.070 |
Why?
|
| Models, Biological | 1 | 2011 | 471 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 50 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 58 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 36 | 0.070 |
Why?
|
| Time Factors | 2 | 2013 | 1619 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2009 | 45 | 0.070 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 67 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2009 | 120 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Viscosity | 1 | 2008 | 40 | 0.070 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 10 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 272 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 468 | 0.070 |
Why?
|
| Permeability | 1 | 2008 | 61 | 0.070 |
Why?
|
| Bacterial Typing Techniques | 2 | 2006 | 133 | 0.070 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 93 | 0.070 |
Why?
|
| Protein Transport | 1 | 2008 | 158 | 0.070 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2007 | 2 | 0.060 |
Why?
|
| Antigens, Protozoan | 1 | 2007 | 9 | 0.060 |
Why?
|
| Morbidity | 1 | 2007 | 60 | 0.060 |
Why?
|
| Blindness | 1 | 2007 | 34 | 0.060 |
Why?
|
| Anterior Eye Segment | 1 | 2006 | 4 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 21 | 0.060 |
Why?
|
| Peptide Hydrolases | 2 | 1997 | 22 | 0.060 |
Why?
|
| Connective Tissue Cells | 1 | 2006 | 1 | 0.060 |
Why?
|
| Global Health | 1 | 2007 | 55 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2006 | 28 | 0.060 |
Why?
|
| Protozoan Proteins | 1 | 2007 | 54 | 0.060 |
Why?
|
| Toxoplasma | 1 | 2007 | 33 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 157 | 0.060 |
Why?
|
| Cell Line | 1 | 2008 | 705 | 0.060 |
Why?
|
| Movement | 1 | 2006 | 100 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2009 | 486 | 0.060 |
Why?
|
| Prognosis | 1 | 2007 | 817 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2009 | 643 | 0.050 |
Why?
|
| Base Sequence | 2 | 2002 | 589 | 0.050 |
Why?
|
| Enterococcus faecalis | 2 | 2007 | 71 | 0.050 |
Why?
|
| Type C Phospholipases | 1 | 2002 | 31 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 1 | 2002 | 39 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 110 | 0.050 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2002 | 68 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 1999 | 132 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 50 | 0.040 |
Why?
|
| Life Style | 1 | 2022 | 91 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2022 | 54 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Synovitis | 1 | 2020 | 6 | 0.040 |
Why?
|
| Arthritis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Biofilms | 1 | 2022 | 125 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2020 | 52 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2002 | 207 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2002 | 256 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 118 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2019 | 24 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 83 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 514 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 490 | 0.030 |
Why?
|
| Corneal Stroma | 2 | 1997 | 7 | 0.030 |
Why?
|
| Prednisolone | 2 | 1995 | 6 | 0.030 |
Why?
|
| Transcription Factors | 2 | 1997 | 524 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 1996 | 4 | 0.030 |
Why?
|
| Tears | 1 | 1996 | 10 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 66 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 789 | 0.030 |
Why?
|
| Random Allocation | 2 | 1993 | 152 | 0.030 |
Why?
|
| Pneumococcal Infections | 1 | 1995 | 24 | 0.030 |
Why?
|
| Administration, Topical | 1 | 1994 | 31 | 0.030 |
Why?
|
| Iontophoresis | 1 | 1994 | 3 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1994 | 36 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 72 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1994 | 79 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 225 | 0.020 |
Why?
|
| Leukopenia | 1 | 1993 | 5 | 0.020 |
Why?
|
| Drug Carriers | 1 | 1994 | 119 | 0.020 |
Why?
|
| Injections, Intraocular | 1 | 2013 | 6 | 0.020 |
Why?
|
| Conjunctiva | 1 | 2013 | 14 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 2013 | 10 | 0.020 |
Why?
|
| Keratitis, Herpetic | 1 | 1993 | 4 | 0.020 |
Why?
|
| Needles | 1 | 2013 | 26 | 0.020 |
Why?
|
| Biological Assay | 1 | 1993 | 34 | 0.020 |
Why?
|
| Virus Replication | 1 | 1993 | 66 | 0.020 |
Why?
|
| DNA Fingerprinting | 2 | 2001 | 7 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 170 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 234 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 697 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 586 | 0.020 |
Why?
|
| Plasmids | 2 | 1998 | 127 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2007 | 20 | 0.020 |
Why?
|
| Propionibacterium acnes | 1 | 2007 | 1 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 1057 | 0.020 |
Why?
|
| Microscopy | 1 | 2007 | 38 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 120 | 0.020 |
Why?
|
| Liver | 1 | 2008 | 497 | 0.010 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 23 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 59 | 0.010 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2002 | 34 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 208 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2002 | 161 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 247 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 2001 | 9 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 417 | 0.010 |
Why?
|
| Phylogeny | 1 | 2001 | 500 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1998 | 4 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1998 | 6 | 0.010 |
Why?
|
| Cytotoxins | 1 | 1998 | 51 | 0.010 |
Why?
|
| Genome, Bacterial | 1 | 1998 | 75 | 0.010 |
Why?
|
| Iritis | 1 | 1997 | 1 | 0.010 |
Why?
|
| Scleritis | 1 | 1997 | 1 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 24 | 0.010 |
Why?
|
| Sclera | 1 | 1997 | 11 | 0.010 |
Why?
|
| Edema | 1 | 1997 | 18 | 0.010 |
Why?
|
| Corneal Diseases | 1 | 1997 | 25 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 40 | 0.010 |
Why?
|
| Species Specificity | 1 | 1997 | 197 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1997 | 64 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1996 | 19 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1996 | 5 | 0.010 |
Why?
|
| Norfloxacin | 1 | 1996 | 4 | 0.010 |
Why?
|
| Gene Expression | 1 | 1998 | 418 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1996 | 22 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1996 | 131 | 0.010 |
Why?
|
| Streptolysins | 1 | 1995 | 18 | 0.010 |
Why?
|
| Complement Activation | 1 | 1995 | 27 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1993 | 28 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 526 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1993 | 794 | 0.000 |
Why?
|